NO974371L - Epitelialadhesive lactobacilli - Google Patents

Epitelialadhesive lactobacilli

Info

Publication number
NO974371L
NO974371L NO974371A NO974371A NO974371L NO 974371 L NO974371 L NO 974371L NO 974371 A NO974371 A NO 974371A NO 974371 A NO974371 A NO 974371A NO 974371 L NO974371 L NO 974371L
Authority
NO
Norway
Prior art keywords
mannose
plantarum
specific
lactobacilli
pharmaceutical composition
Prior art date
Application number
NO974371A
Other languages
English (en)
Norwegian (no)
Other versions
NO974371D0 (no
Inventor
Ingegerd Adlerberth
Siv Ahrne
Bengt Jeppsson
Marie-Louise Johansson
Goeran Molin
Agnes Wold
Acen Andonov
Original Assignee
Probi Ab
Acen Andonov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab, Acen Andonov filed Critical Probi Ab
Publication of NO974371D0 publication Critical patent/NO974371D0/no
Publication of NO974371L publication Critical patent/NO974371L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
NO974371A 1995-03-23 1997-09-22 Epitelialadhesive lactobacilli NO974371L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501056A SE9501056D0 (sv) 1995-03-23 1995-03-23 Epithelial adherent lactobacilli
PCT/SE1996/000372 WO1996029083A1 (en) 1995-03-23 1996-03-25 Epithelial adhesive lactobacilli

Publications (2)

Publication Number Publication Date
NO974371D0 NO974371D0 (no) 1997-09-22
NO974371L true NO974371L (no) 1997-11-20

Family

ID=20397666

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974371A NO974371L (no) 1995-03-23 1997-09-22 Epitelialadhesive lactobacilli

Country Status (16)

Country Link
US (1) US6159465A (de)
EP (1) EP0817640B1 (de)
JP (1) JP4072646B2 (de)
KR (1) KR100446482B1 (de)
CN (1) CN1138551C (de)
AT (1) ATE240738T1 (de)
AU (1) AU702705B2 (de)
BR (1) BR9607538A (de)
CA (1) CA2216150C (de)
DE (1) DE69628288T2 (de)
EE (1) EE04097B1 (de)
ES (1) ES2200057T3 (de)
NO (1) NO974371L (de)
PL (1) PL184037B1 (de)
SE (1) SE9501056D0 (de)
WO (1) WO1996029083A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100376954B1 (ko) * 1995-07-31 2003-07-18 프로비 에이비 장에서집락화하는유산간균
DK1003532T4 (da) * 1997-07-05 2009-03-02 Nestle Sa Lactobacilli til fremme af tarmcellers mineralabsorption
FI974643A7 (fi) * 1997-12-30 1999-07-01 Suomen Rehu Oy Biologinen menetelmä salmonellan eliminoimiseksi prosesseista ja rakenteista
EP1117414A1 (de) * 1998-10-01 2001-07-25 Probi Ab Reduktion von faktoren des oxidativen stresses
WO2001010448A1 (en) * 1999-08-09 2001-02-15 University Of Maryland, Baltimore Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids
PT1227827E (pt) * 1999-10-26 2005-07-29 Nestle Sa Bacterias acido-lacticas para o tratamento e/ou profilaxia da giardiase
GB2369777B (en) * 2000-10-05 2004-10-27 St Ivel Ltd Food products with antimicrobial lactic acid bacteria
SE0004124D0 (sv) * 2000-11-10 2000-11-10 Probi Ab New use
FR2831555A1 (fr) * 2001-10-29 2003-05-02 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes capables de lutter contre des infections par des bacteries pathogenes
FR2826020B1 (fr) * 2001-06-14 2005-02-11 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes capables de lutter contre des infections par des bacteries pathogenes
EP1395672A1 (de) * 2001-06-14 2004-03-10 Ceva Sante Animale Verfahren zur auswählung von gram-positiven nicht-pathogenen bakterienstämme
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
WO2005086870A2 (en) * 2004-03-10 2005-09-22 The Board Of Trustees Of The University Of Illinois Novel lactobacillus strains and method of use
WO2005090396A1 (en) * 2004-03-23 2005-09-29 N.V. Nutricia Novel mannose-specific adhesins and their use
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
JP2006180836A (ja) * 2004-12-28 2006-07-13 Marudai Food Co Ltd 食中毒菌感染を抑制する乳酸菌、ならびにそれを含む発酵物、食品および医薬組成物
JP2006257077A (ja) * 2005-02-18 2006-09-28 Marudai Food Co Ltd 免疫調節剤および免疫調節食品
CN1888051B (zh) * 2005-06-28 2010-05-05 北京天佑达生物工程科技有限公司 一株植物乳杆菌及其应用
SE529199C2 (sv) * 2005-07-05 2007-05-29 Probi Ab Förstärkt absorption
DK1931363T3 (en) 2005-09-28 2016-02-22 Nordisk Rebalance As Treatment of IBD using both probiotic bacteria and fermented cereal as behandlingseffektorer
WO2007069983A1 (en) 2005-12-13 2007-06-21 Exthera Ab Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
FR2928935B1 (fr) 2008-03-19 2011-05-20 Gervais Danone Sa Souche de lactobacillus rhamnosus.
DK2459203T3 (en) 2009-07-30 2019-02-18 Dupont Nutrition Biosci Aps Lactic Acid Bacteria and Bifidobacteria for the Treatment of Endotoxemia
JP5925693B2 (ja) 2009-12-01 2016-05-25 エクステラ・メディカル・コーポレーション 表面固定した多糖類を用いた、血液からのサイトカイン除去法
WO2011092261A1 (en) 2010-01-28 2011-08-04 Ab-Biotics S.A. Probiotic composition for use in the treatment of bowel inflammation
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
BG66608B1 (bg) * 2011-05-04 2017-10-16 "Ел Би Булгарикум" ЕАД Полибактериален пробиотичен препарат
CN102618456B (zh) * 2012-02-28 2013-08-21 江南大学 一种能够缓解慢性酒精性肝损伤的鼠李糖乳杆菌及其用途
ES2647577T3 (es) 2012-06-13 2017-12-22 Exthera Medical Corporation Uso de heparina y carbohidratos para tratar el cáncer
JP2012184261A (ja) * 2012-06-21 2012-09-27 Snow Brand Milk Products Co Ltd 免疫増強剤
CN102827796B (zh) * 2012-09-03 2013-10-30 江南大学 一种具有排镉功能的植物乳杆菌及其用途
EP2897638A1 (de) 2012-09-24 2015-07-29 Montana State University-Bozeman Rekombinanter lactococcus lactis zur expression des escherichia coli-kolonisationsfaktor-antigens i (cfa/i) fimbriae und verfahren zu deren verwendung
CN105339067A (zh) 2013-06-24 2016-02-17 艾克塞拉医疗公司 含有涂覆甘露糖的基质的血液过滤系统
EP3065796B1 (de) 2013-11-08 2020-04-15 ExThera Medical Corporation Verfahren zur diagnose von infektionskrankheiten unter verwendung von adsorptionsmedien
JP2017513636A (ja) 2014-04-24 2017-06-01 エクスセラ メディカル コーポレイション 高流量を用いて血液から細菌を除去するための方法
CA2959975A1 (en) 2014-09-22 2016-03-31 Exthera Medical Corporation Wearable hemoperfusion device
US11166968B2 (en) 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
WO2017151797A1 (en) 2016-03-02 2017-09-08 Exthera Medical Corporation Method for treating drug intoxication
KR102769558B1 (ko) 2017-02-28 2025-02-19 킴벌리-클라크 월드와이드, 인크. 미생물총의 건강한 균형을 유지하기 위한 상승적 조성물
WO2019103198A1 (ko) 2017-11-24 2019-05-31 주식회사 고바이오랩 락토바실러스 퍼멘텀 kbl 375 균주 및 그 용도
EP4733390A3 (de) 2018-05-09 2026-07-15 Kobiolabs, Inc. Lactobacillus-paracasei-stamm und seine verwendung
MX2020012594A (es) 2018-05-23 2021-04-28 Ko Biolabs Inc Cepa de lactobacillus gasseri kbl697 y uso de la misma.
CN113825517A (zh) 2019-05-16 2021-12-21 艾克塞拉医疗公司 调节内皮糖萼结构的方法
US20220226382A1 (en) 2019-06-05 2022-07-21 Morinaga Milk Industry Co., Ltd. Nutritional Composition
CN111575223B (zh) * 2020-05-20 2022-04-15 江南大学 一种降低鼠李糖乳杆菌表面物质分泌量的方法
CN119242500A (zh) * 2024-09-30 2025-01-03 尚品健康科技(青岛)有限公司 一株母乳来源植物乳植杆菌改善过敏性疾病和调节肠道菌群的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203586A3 (de) * 1985-05-29 1988-03-09 Pioneer Hi-Bred International Zubereitung für die Behandlung von Magen-/Darmstörungen bei Tieren
SE469875C (sv) * 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
GB9124249D0 (en) * 1991-11-14 1992-01-08 Goldstein Fredric Ribbon curling and shredding device
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection

Also Published As

Publication number Publication date
US6159465A (en) 2000-12-12
SE9501056D0 (sv) 1995-03-23
PL322550A1 (en) 1998-02-02
EE9700329A (et) 1998-06-15
CN1185111A (zh) 1998-06-17
EP0817640B1 (de) 2003-05-21
EE04097B1 (et) 2003-08-15
DE69628288T2 (de) 2004-04-08
AU702705B2 (en) 1999-03-04
ATE240738T1 (de) 2003-06-15
AU5166596A (en) 1996-10-08
CA2216150C (en) 2008-01-22
KR100446482B1 (ko) 2006-01-27
EP0817640A1 (de) 1998-01-14
DE69628288D1 (de) 2003-06-26
HK1017989A1 (en) 1999-12-10
KR19980703102A (ko) 1998-10-15
BR9607538A (pt) 1998-01-06
PL184037B1 (pl) 2002-08-30
CA2216150A1 (en) 1996-09-26
CN1138551C (zh) 2004-02-18
NO974371D0 (no) 1997-09-22
WO1996029083A1 (en) 1996-09-26
JP4072646B2 (ja) 2008-04-09
ES2200057T3 (es) 2004-03-01
JPH11502703A (ja) 1999-03-09

Similar Documents

Publication Publication Date Title
SE9501056D0 (sv) Epithelial adherent lactobacilli
Jensen et al. In vitro testing of commercial and potential probiotic lactic acid bacteria
Bleau et al. Intermediate chains of exopolysaccharides from Lactobacillus rhamnosus RW‐9595M increase IL‐10 production by macrophages
Mu et al. Probiotic yeast BR14 ameliorates DSS-induced colitis by restoring the gut barrier and adjusting the intestinal microbiota
Esteban‐Fernández et al. In vitro beneficial effects of Streptococcus dentisani as potential oral probiotic for periodontal diseases
Rios-Covian et al. Bacteroides fragilis metabolises exopolysaccharides produced by bifidobacteria
EP1816190B1 (de) Als Probiotikum verwendbares neues Milchsäurebakterium
HUP9901619A1 (hu) Streptococcus thermophilus és bifidobacterium longum baktériumokat tartalmazó enterális diétás kompozíciók és azok alkalmazása
WO2020074547A8 (en) Lactobacillus crispatus probiotic strains suitable for treating urogenital yeast and bacterial infections
NO306699B1 (no) Tarmkanal-koloniserende lactobasiller, samt fremgangsmåte for isolering og anvendelse derav, samt blanding
Nallala et al. Molecular characterization of antimicrobial Lactobacillus isolates and evaluation of their probiotic characteristics in vitro for use in poultry
MXPA04000808A (es) Cepas probioticas de lactobacillus salivarius.
Nishitani et al. A novel colorimetric method to quantify tannase activity of viable bacteria
VidyaLaxme et al. Synergistic effects of probiotic Leuconostoc mesenteroides and Bacillus subtilis in malted ragi (Eleucine corocana) food for antagonistic activity against V. cholerae and other beneficial properties
Sánchez et al. Identification of novel proteins secreted by Lactobacillus rhamnosus GG grown in de Mann‐Rogosa‐Sharpe broth
Tzvetkova et al. Hydrolysis of major dairy proteins by lactic acid bacteria from Bulgarian yogurts
AU2004241895A1 (en) A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and a fiber fermenting property
Melgar-Lalanne et al. In vitro evaluation of the probiotic potential of halotolerant lactobacilli isolated from a ripened tropical Mexican cheese
NZ335086A (en) Bacillus thuringiensis pesticidal toxins and nucleotide sequences which encode these toxins
Zhu et al. Protective effect of Bifidobacterium animalis CGMCC25262 on HaCaT keratinocytes
Sun et al. Lactobacillus isolates from healthy volunteers exert immunomodulatory effects on activated peripheral blood mononuclear cells
Sophatha et al. Factors relating to adhesion and aggregation of Lactobacillus paracasei and Lactobacillus rhamnosus strains
US5468479A (en) Compositions containing lactic acid bacterium Streptococcus salivarius
Sim et al. In vitro assessment of the gastrointestinal tolerance and immunomodulatory function of Bacillus methylotrophicus isolated from a traditional Korean fermented soybean food
Afrikian Studies of lactic-acid bacteria in Armenia with emphasis on radioprotective properties

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application